Clinical trial
Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer…
NCT00130507 · Spanish Breast Cancer Research Group, Other · Terminated
Key facts
| NCT number | NCT00130507 |
|---|---|
| Title | Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab |
| Official title | Randomized Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line for HER2positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Previously Treated With Trastuzumab and Taxanes |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Vinorelbine, Capecitabine, Trastuzumab |
| Enrollment | 14 |
| Start date | Nov 4, 2005 |
| Primary completion | Jun 1, 2009 |
| Completion | Jul 25, 2009 |
| First posted | Aug 15, 2005 |
| Last update posted | Feb 26, 2019 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: